IDYA
What one share of IDEAYA Biosciences holds
Pharmaceutical Preparations
We are a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease.
IDEAYA Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.96 |
|---|---|
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$1.27 |
| Cash and investments | $12.90 |
| Book value | $12.44 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$17.06 | $2.53 | −$20.11 | — | −$22.63 |
| 2018 | — | −$35.92 | $1.79 | −$30.67 | — | −$36.65 |
| 2019 | $0.00 | −$3.36 | $0.11 | −$3.25 | — | $4.94 |
| 2020 | $0.79 | −$1.40 | $0.02 | $2.22 | — | $6.71 |
| 2021 | $0.79 | −$1.41 | $0.07 | −$1.66 | — | $7.82 |
| 2022 | $1.23 | −$1.42 | $0.08 | −$2.19 | — | $7.25 |
| 2023 | $0.41 | −$1.96 | $0.04 | −$2.04 | — | $9.55 |
| 2024 | $0.09 | −$3.36 | $0.05 | −$3.08 | — | $12.24 |
| 2025 | $2.47 | −$1.28 | $0.03 | −$0.83 | — | $11.65 |